Physician profile
Alan M Keller
NPI 1386696011
$738.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $94.51 · 2021: $235 · 2022: $218 · 2023: $46.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $25.60 · Food and Beverage: $21.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $25.60 |
| Food and Beverage | $21.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $158.70 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $105.00 | 2022 | |
| Epizyme, INC. | $103.43 | 2021 | |
| Pfizer INC. | $62.43 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.13 | 2020-2023 | Enhertu |
| Seagen INC. | $48.07 | 2020-2021 | |
| Acrotech Biopharma INC. | $39.83 | 2021-2022 | |
| Genzyme Corporation | $26.38 | 2022 | |
| Astellas Pharma US INC | $18.00 | 2020 | |
| Amgen INC. | $17.66 | 2020 | |
| Merck Sharp & Dohme LLC | $17.04 | 2022 | |
| Celgene Corporation | $16.62 | 2021 | |
| Abbvie INC. | $16.52 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.48 | 2019 | |
| Genentech USA, INC. | $12.39 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Puma Biotechnology, INC. | $11.88 | 2020 | |
| Daiichi Sankyo INC. | $11.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.